BioDirection, a privately held medical device company developing novel and rapid point-of-care products for the objective detection of concussion and other traumatic brain injury (TBI), today announced that it recently filed a Pre-Submission (“Pre-Sub”) Package with the FDA as a critical step toward commercialization of its proprietary Tbit™ diagnostic platform.
BioDirection’s Pre-Sub meeting with FDA to discuss clinical plans and protocols for the company’s Tbit™ system, which is a necessary precursor to commencement of clinical trials, has been scheduled for November 2016.
“This Pre-Sub filing is a critical milestone in the path to commercialize our game-changing technology,” said Eric Goorno, President & CEO of BioDirection. “Tbit™ is truly a disruptive diagnostic platform which has the potential to revolutionize the detection, diagnosis and management of a concussion. We look forward to commencing our clinical trials and advancing to the final stages of FDA regulatory review and product registration.”
The Tbit™ system uses a patented nanotechnology biosensor to rapidly detect and accurately measure protein biomarkers that are released from the brain immediately following a head trauma. The portable system allows for testing to be performed at the earliest stages of medical diagnosis and intervention. Early objective diagnostic testing of patients who have experienced head trauma allows for more rapid and appropriate treatment decisions, while potentially reducing unnecessary head CT scans.
Brian McGlynn, Founder, Executive Vice President and CTO of BioDirection, expanded on the potential benefits of Tbit™. “We are addressing an enormous, global unmet medical need with a truly amazing technical platform. Tbit™’s ability to quantitatively measure protein biomarkers associated with brain injury at ng/mL concentrations offers the potential to aid in concussion prognosis and unbiased return to play/activity decision making. Tbit™ is the first step in rapid and affordable, real-time data to improve diagnosis and patient safety.”
BioDirection, Inc. is a privately held medical device company developing novel and rapid point-of-care technologies for the objective diagnosis and management of concussion and other traumatic brain injury (TBI). The company’s lead product, the Tbit™ blood test, delivers rapid biologically-based results to accurately confirm a traumatic brain injury/concussion. BioDirection’s platform system utilizes a patented bio-nanowire technology with the potential for use in a range of applications in point-of-care diagnostics. To learn more about BioDirection visit http://www.biodirection.com.
View source version on businesswire.com: http://www.businesswire.com/news/home/20161004005972/en/Business Wire
Last updated on: 04/10/2016
PharmiWeb.com is Europe's leading industry-sponsored portal for the Pharmaceutical sector, providing the latest jobs, news, features and events listings.
The information provided on PharmiWeb.com is designed to support, not replace, the relationship that exists between a patient/site visitor and his/her physician.